Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-09-29
2010-12-14
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S143100, C424S178100, C530S387100, C530S388220, C530S388800, C530S389700
Reexamination Certificate
active
07850961
ABSTRACT:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan
patent: 4109496 (1978-08-01), Allemann
patent: 4323546 (1982-04-01), Crockford
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4670393 (1987-06-01), Seeburg
patent: 4873191 (1989-10-01), Wagner
patent: 4968103 (1990-11-01), McNab
patent: 4981785 (1991-01-01), Nayak
patent: 5019497 (1991-05-01), Olsson
patent: 5034506 (1991-07-01), Summerton
patent: 5223409 (1993-06-01), Ladner
patent: 5225539 (1993-07-01), Winter
patent: 5283317 (1994-02-01), Saifer
patent: 5358691 (1994-10-01), Clark
patent: 5489677 (1996-02-01), Sanghvi
patent: 5534617 (1996-07-01), Cunningham
patent: 5538848 (1996-07-01), Livak
patent: 5539082 (1996-07-01), Nielsen
patent: 5565332 (1996-10-01), Hoogenboom
patent: 5585089 (1996-12-01), Queen
patent: 5599677 (1997-02-01), Dowell
patent: 5602240 (1997-02-01), de Mesmaeker
patent: 5614396 (1997-03-01), Bradley
patent: 5631169 (1997-05-01), Lakowicz
patent: 5639606 (1997-06-01), Willey
patent: 5643765 (1997-07-01), Willey
patent: 5648464 (1997-07-01), Artavanis-Tsakonas
patent: 5674739 (1997-10-01), Shyjan
patent: 5688666 (1997-11-01), Bass
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5714331 (1998-02-01), Buchardt
patent: 5719262 (1998-02-01), Buchardt
patent: 5750373 (1998-05-01), Garrard
patent: 5753229 (1998-05-01), Mordoh et al.
patent: 5786158 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5824544 (1998-10-01), Armentano
patent: 5830730 (1998-11-01), German
patent: 5834598 (1998-11-01), Lowman
patent: 5849535 (1998-12-01), Cunningham
patent: 5854026 (1998-12-01), Cunningham
patent: 5859535 (1999-01-01), Liu
patent: 5872154 (1999-02-01), Wilson
patent: 5876978 (1999-03-01), Willey
patent: 5885530 (1999-03-01), Babson
patent: 5885808 (1999-03-01), Spooner
patent: 5981225 (1999-11-01), Kochanek
patent: 5986170 (1999-11-01), Subjeck
patent: 5994106 (1999-11-01), Kovesdi
patent: 5994128 (1999-11-01), Fallaux
patent: 5994132 (1999-11-01), Chamberlain
patent: 6001557 (1999-12-01), Wilson
patent: 6019978 (2000-02-01), Ertl
patent: 6022711 (2000-02-01), Cunningham
patent: 6033908 (2000-03-01), Bout et al.
patent: 6054297 (2000-04-01), Carter
patent: 6080912 (2000-06-01), Bremel
patent: 6117985 (2000-09-01), Thomas et al.
patent: 6121045 (2000-09-01), McCarthy et al.
patent: 6135653 (2000-10-01), Aichi
patent: 6136563 (2000-10-01), Cunningham
patent: 6143523 (2000-11-01), Cunningham
patent: 6156305 (2000-12-01), Brauker
patent: 6159750 (2000-12-01), Edmonds
patent: 6180370 (2001-01-01), Queen
patent: 6198107 (2001-03-01), Seville
patent: 6207147 (2001-03-01), Hiserodt
patent: 6218166 (2001-04-01), Ravindranath
patent: 6262025 (2001-07-01), Ish-Horowicz
patent: 6379925 (2002-04-01), Kitajewski et al.
patent: 6664098 (2003-12-01), Sakano
patent: 6689744 (2004-02-01), Gao et al.
patent: 6894522 (2005-05-01), Averill
patent: 2006/0083682 (2006-04-01), Bergstein
patent: 2009/0011441 (2009-01-01), Bergstein
patent: 2009/0022740 (2009-01-01), Bergstein
patent: 2009/0028878 (2009-01-01), Bergstein
patent: 1004669 (1998-05-01), None
patent: 0861894 (1998-09-01), None
patent: 90/08832 (1990-08-01), None
patent: 92/19734 (1992-11-01), None
patent: 94/07474 (1994-04-01), None
patent: 94/10300 (1994-05-01), None
patent: 97/01571 (1997-01-01), None
patent: 97/30731 (1997-08-01), None
patent: 98/45434 (1998-10-01), None
patent: 98/51799 (1998-11-01), None
patent: 9902685 (1999-01-01), None
patent: 00/09675 (2000-02-01), None
patent: 00/12738 (2000-03-01), None
patent: 01/98537 (2001-12-01), None
US 5,962,233, 10/1999, Livak (withdrawn)
Lee et al. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias. APMIS 115: 1357-1363, 2007.
Song et al. Cancer stem cells—an old idea that's new again: implication for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther 7(4): 431-438, 2007.
Allenspach et al. Notch Signaling in Cancer. Cancer Biol Ther 1(5): 466-476, 2002.
Van Es et al. Notch/gamma secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963, 2005.
Fre et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435: 964-968, 2005.
Tannock and Hill. The Basic Science of Oncology. 1998. New York: McGraw-Hill, pp. 357-358 and 370-372.
Osawa, M. et al.: ‘Long-term lymphohematopoietic reconstitution by a single CD34-low
egative hematopoietic stem cell’ Science vol. 273, 1996, pp. 242-245.
Domen, J.; Weissman, I. L.: ‘Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other’ J Exp Med vol. 192, 2000, pp. 1707-1718.
Miller etla, 1999, Oncogene 18: 7860-72.
Miller, C. L.; Eaves, C. J.: ‘Expansion in vitro of adult murine hematopoietc stem cells with transplantable lympho-myeloid reconstituting ability’ Proc Natl Acad Sci USA vol. 94, 1997, pp. 13648-13653.
Hanahan, D.; Weinberg, R. A.: ‘The hallmarks of cancer’ Cell vol. 100, 2000, pp. 57-70.
Phillips, R. L.; Reinhart, A. J.; Van Zant, G.: ‘Genetic control of murine hematopoietic stem cell pool sizes and cycling kinetics’ Proc Natl Acad Sci U SA vol. 89, 1992, pp. 11607-11611.
Muller-Sieburg, C. E. et al.: ‘Genetic control of hematopoietic stem cell frequency in mice is mostly cell autonomous’ Blood vol. 95, 2000, pp. 2446-2448.
Domen, J.; Cheshier, S. H.; Weissman, I. L.: ‘The Role of Apoptosis in the Regulation of Hematopoietic Stem Cells: Overexpression of BCL-2 Increases Both Their Number and Repopulation Potential’ 1. Exp. Med. vol. 191, 2000, pp. 253-264.
Varnum-Finney, B. et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 6, 1278-81 (2000).
Christensen, S., Kodoyianni, V., Bosenberg, M., Friedman, L. & Kimble, J. Iag-1, a gene required for lin-12 and glp-1 signaling inCaenohabditis elegans, is homologous to human CBF-1 and Drosophila Su(H). Development 122, 1373-83 (1996).
Imatani, A. & Callahan, R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 19,223-231 (2000).
Petcherski, A. G. & Kimble, J. Mastermind is a putative activator for Notch. Curr Bioi 10, R471-3 (2000).
Korinek, V. et al. Two members of the Tcf family implicated in WnUbeta-catenin signaling during embryogenesis in the mouse. Mol Cell Bioi 18, 1248-56 (1998).
L1vak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-8 (2001).
Yan, X.-Q., et al., “A novel Notch ligand, D1I4, induces T-celileukemiallymphoma when overexpressed in mice by retroviral-mediated gene transfer,” Blood 98:3793-3799, the American Society of Hematology, Washington, DC, U.S.A. (2001).
Miele, L. and Osborne, B., Arbiter of Differentiation and Death: Notch Signaling Meets Apoptosis, Journal of Cellular Physiology 181:393-409, Wiley-Liss, Inc. (1999).
Bellavia, D., et al., “Constitutive activation of NF-KBand T-cell leukemia/lymphoma in Notch3 transgenic mice,” EM
Al-Hajj Muhammad
Clarke Michael F.
Morrison Sean J.
Wicha Max S.
Bunner Bridget E
Casimir Jones S.C.
The Regents of The University of Michigan
LandOfFree
Methods for targeting solid tumor stem cells in a solid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for targeting solid tumor stem cells in a solid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for targeting solid tumor stem cells in a solid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4238164